|
Home > Investor
Center
Investor Center
OXiGENE is highly committed to delivering value to its shareholders.
With a pipeline of high-potential therapeutic candidates that have demonstrated promising results to date in clinical trials, and a highly experienced management team, we're working to translate innovative science into important, next-generation therapeutic products that deliver significant medical benefits to patients suffering from cancer and eye disease.
OXiGENE is listed on the Nasdaq National Market and the
Stockholm Stock Exchange under the symbol "OXGN."
OXiGENE is headquartered in Waltham, Massachusetts. By
maintaining operations in key biomedical research centers in the U.S. and
Europe, we have been able to develop strong collaborative relationships with
leading universities and research institutes on both continents.
| 
